BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34625389)

  • 1. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
    Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
    Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
    Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
    Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
    Kaya AO; Coskun U; Ozkan M; Sevinc A; Yilmaz AU; Gumus M; Unal OU; Ozdemir NY; Alici S; Berk V; Degerli H; Oner MK; Ozturk C; Kefeli U; Camcı C;
    Onkologie; 2012; 35(10):576-80. PubMed ID: 23038228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
    Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
    Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
    Roubaud G; Gross-Goupil M; Wallerand H; de Clermont H; Dilhuydy MS; Ravaud A
    Oncology; 2011; 80(3-4):214-8. PubMed ID: 21720184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
    Haas NB; Lin X; Manola J; Pins M; Liu G; McDermott D; Nanus D; Heath E; Wilding G; Dutcher J
    Med Oncol; 2012 Jun; 29(2):761-7. PubMed ID: 21298497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
    Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
    Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
    Park I; Lee HJ; Bae WK; Yoon S; Lee JL
    Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
    Staehler M; Haseke N; Roosen A; Stadler T; Bader M; Siebels M; Karl A; Stief CG
    Eur J Med Res; 2010; 15(7):287-91. PubMed ID: 20696639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
    Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
    Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
    Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.